Understand the source comparison
Epithalon vs Alternative Sleep-Regulating Peptides: Clinical Comparison
Epithalon is frequently compared to other peptides marketed for sleep support, but the mechanisms differ fundamentally. The table below contrasts clinical data across the most researched compounds. Epithalon Telomerase activation in pineal tissue 5–10mg nightl
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Epithalon is frequently compared to other peptides marketed for sleep support, but the mechanisms differ fundamentally. The table below contrasts clinical data across the most researched compounds.
- Epithalon
- Telomerase activation in pineal tissue
- 5–10mg nightly × 10 days
- 10–14 days
- 3–6 months post-cycle
- Phase II trials, peer-reviewed (moderate)
- DSIP (Delta Sleep-Inducing Peptide)
- Direct CNS sedation via unknown receptor
- 10–50mcg IV or subcutaneous
- 20–40 minutes
- Duration of plasma presence (~2 hours)
- Preliminary studies, inconsistent replication (low)
- Selank
- Anxiolytic via BDNF upregulation
- 300–600mcg intranasal daily
- 3–7 days
- Ongoing during administration
- Phase III anxiety trials, sleep as secondary endpoint (moderate)
- MK 677
- Growth hormone secretagogue (ghrelin agonist)
- 10–25mg oral nightly
- Immediate (GH pulse-related)
- Phase II metabolic trials, sleep architecture as measured outcome (high)
- Melatonin (reference)
- Exogenous MT1/MT2 receptor agonism
- 0.5–5mg oral
- 30–60 minutes
- 4–6 hours
- Meta-analyses available, dose-response established (high)
- Epithalon stands apart because its benefit persists long after administration stops. This is the telltale signature of a restorative mechanism rather than a suppressive one. DSIP acts as a sedative with no lasting effect once cleared. MK 677 improves sleep architecture through growth hormone pulses but requires continuous nightly dosing. Epithalon's 10-day cycle producing 3–6 months of benefit reflects genuine biological repair.